Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 10–11

HOS-114813 · Präparat HOS-094169

10 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Efavirenz 600 mg QD No clinically significant No dosage adjustment necessary. interaction is observed. Etravirine Etravirine Cmax ↓ 71% Co-administration of etravirine Etravirine AUC ↓ 76% and Aptivus/ritonavir is not Etravirine Cmin ↓ 82% recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): etravirine (HOS-088088) efavirenz (HOS-087947) ritonavir (HOS-084521)

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 11

HOS-114814 · Präparat HOS-094169

Concomitant use of Aptivus/ritonavir caused a decrease of etravirine exposure that could significantly impair the virologic response to etravirine. Nevirapine The limited data available from a No dosage adjustment necessary. No interaction study phase IIa study in HIV-infected performed patients suggest that no significant interaction is expected between nevirapine and TPV/r. Moreover a study with TPV/r and another NNRTI (efavirenz) did not show any clinically relevant interaction (see above). Rilpivirine Concomitant use of rilpivirine Close monitoring for signs of No interaction study with some ritonavir-boosted rilpivirine toxicity and possibly performed protease inhibitors has also dose adjustment of rilpivirine demonstrated an increase in the is recommended when co- plasma concentrations of administered with rilpivirine. Aptivus/ritonavir. Protease inhibitors (PIs) According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended Amprenavir/ritonavir Amprenavir Cmax ↓ 39% The concomitant use of Aptivus, 600/100 mg BID Amprenavir AUC ↓ 44% co-administered with low dose Amprenavir Cmin ↓ 55% ritonavir, with amprenavir/ritonavir is not The clinical relevance of this recommended. reduction in amprenavir If the combination is nevertheless concentrations has not been considered necessary, a established. monitoring of the plasma levels of amprenavir is strongly Mechanism unknown. encouraged (see section 4.4). Atazanavir/ritonavir Atazanavir Cmax ↓ 57% The concomitant use of Aptivus, 300/100 mg QD Atazanavir AUC ↓ 68% co-administered with low dose (TPV/r 500/100 mg BID) Atazanavir Cmin ↓ 81% ritonavir, with atazanavir/ritonavir is not Mechanism unknown. recommended. If the co-administration is Tipranavir Cmax  8% nevertheless considered Tipranavir AUC  20% necessary, a close monitoring of Tipranavir Cmin  75% the safety of tipranavir and a monitoring of plasma Inhibition of CYP 3A4 by concentrations of atazanavir are atazanavir/ritonavir and strongly encouraged (see induction by tipranavir/r. section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180) protease (HOS-085623) etravirine (HOS-088088) amprenavir (HOS-086183) rilpivirine (HOS-088090) efavirenz (HOS-087947) nevirapine (HOS-088064) ritonavir (HOS-084521)

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 11–12

HOS-114815 · Präparat HOS-094169

11 Lopinavir/ritonavir Lopinavir Cmax ↓ 47% The concomitant use of Aptivus, 400/100 mg BID Lopinavir AUC ↓ 55% co-administered with low dose Lopinavir Cmin ↓ 70% ritonavir, with lopinavir/ritonavir is not recommended. The clinical relevance of this If the combination is nevertheless reduction in lopinavir considered necessary, a concentrations has not been monitoring of the plasma levels of established. lopinavir is strongly encouraged (see section 4.4). Mechanism unknown. Saquinavir/ritonavir Saquinavir Cmax ↓ 70% The concomitant use of Aptivus, 600/100 mg QD Saquinavir AUC ↓ 76% co-administered with low dose Saquinavir Cmin ↓ 82% ritonavir, with saquinavir/ritonavir is not The clinical relevance of this recommended. reduction in saquinavir If the combination is nevertheless concentrations has not been considered necessary, a established. monitoring of the plasma levels of saquinavir is strongly encouraged Mechanism unknown. (see section 4.4). Protease inhibitors other No data are currently available Combination with Aptivus, co- than those listed above on interactions of tipranavir, co- administered with low dose administered with low dose ritonavir, is not recommended ritonavir, with protease inhibitors (see section 4.4) other than those listed above. Fusion inhibitors Enfuvirtide In studies where tipranavir co- The clinical impact of the No interaction study administered with low-dose observed data, especially performed ritonavir was used with or regarding the tipranavir with without enfuvirtide, it has been ritonavir safety profile, remains observed that the steady-state unknown. Nevertheless, the plasma tipranavir trough clinical data available from the concentration of patients RESIST trials did not suggest any receiving enfuvirtide were 45% significant alteration of the higher as compared to patients tipranavir with ritonavir safety not receiving enfuvirtide. No profile when combined with information is available for the enfuvirtide as compared to parameters AUC and Cmax. patients treated with tipranavir A pharmacokinetic interaction is with ritonavir without enfuvirtide. mechanistically unexpected and the interaction has not been confirmed in a controlled interaction study. Integrase strand transfer inhibitors Raltegravir 400 mg BID Raltegravir Cmax ↔ No particular dose adjustment is Raltegravir AUC 0-12↔ recommended when Raltegravir C12: ↓ 45% Aptivus/ritonavir is administered with Raltegravir 400 mg BID. Despite an almost half reduction For other doses of raltegravir, of C12, previous clinical studies please refer to the relevant with this combination did not product information for evidence an impaired outcome. raltegravir..

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): enfuvirtide (HOS-088107) lopinavir (HOS-086269) protease (HOS-085623) saquinavir (HOS-084522) raltegravir (HOS-086187) ritonavir (HOS-084521)

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 12

HOS-114816 · Präparat HOS-094169

The mechanism of action is thought to be induction of glucuronosyltransferase by tipranavir/r.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 12–13

HOS-114817 · Präparat HOS-094169

12 Dolutegravir 50 mg QD Dolutegravir ↓ The recommended adult dose of AUC ↓ 59% dolutegravir is 50 mg twice daily Cmax ↓ 47% when co-administered with Cτ ↓ 76% tipranavir/ritonavir. In the (induction of UGT1A1 and presence of integrase class CYP3A enzymes) resistance this combination should be avoided (see dolutegravir SmPC).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dolutegravir (HOS-089992) ritonavir (HOS-084521)

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 13

HOS-114818 · Präparat HOS-094169

Pharmacokinetic enhancer Cobicistat and cobicistat- When co-administered, tipranavir Aptivus/ritonavir should not be containing products and cobicistat exposures are administered concomitantly with markedly lower compared to that cobicistat or cobicistat-containing of tipranavir when boosted with products. low dose ritonavir. Antifungals Fluconazole 200 mg QD Fluconazole ↔ No dosage adjustments are (Day 1) then 100 mg QD recommended. Fluconazole doses Tipranavir Cmax ↑ 32% > 200 mg/day are not Tipranavir AUC ↑ 50% recommended. Tipranavir Cmin ↑ 69%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cobicistat (HOS-088111) fluconazole (HOS-087945) ritonavir (HOS-084521)

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 13

HOS-114819 · Präparat HOS-094169

Mechanism unknown Itraconazole Based on theoretical Itraconazole or ketoconazole Ketoconazole considerations tipranavir, co- should be used with caution No interaction study administered with low dose (doses > 200 mg/day are not performed ritonavir, is expected to increase recommended). itraconazole or ketoconazole concentrations.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) itraconazole (HOS-084516) ritonavir (HOS-084521)

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 13

HOS-114820 · Präparat HOS-094169

Based on theoretical considerations, tipranavir or ritonavir concentrations might increase upon co-administration with itraconazole or ketoconazole. Voriconazole Due to multiple CYP isoenzyme Based on the known interaction No interaction study systems involved in voriconazole of voriconazole with low dose performed metabolism, it is difficult to ritonavir (see voriconazole predict the interaction with SmPC) the co-administration of tipranavir, co-administered with tipranavir/r and voriconazole low-dose ritonavir. should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole. Anti-gouts Colchicine Based on theoretical A reduction in colchicine dosage No interaction study considerations, colchicine or an interruption of colchicine performed concentrations may increase upon treatment is recommended in co-administration with tipranavir patients with normal renal or and low dose ritonavir, due to hepatic function if treatment with tipranavir/ritonavir CYP3A and Aptivus/ritonavir is required (see P-gp inhibition. However a section 4.4). decrease of colchicine In patients with renal or hepatic concentrations cannot be impairment, co-administration of excluded since both tipranavir colchicine in patients on and ritonavir exhibit inducing

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) voriconazole (HOS-084524) itraconazole (HOS-084516) colchicine (HOS-086147) ritonavir (HOS-084521)

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 13–14

HOS-114821 · Präparat HOS-094169

13  potential towards CYP3A and Aptivus/ritonavir is P-gp. contraindicated (see section 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521)

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 14

HOS-114822 · Präparat HOS-094169

Colchicine is a substrate of CYP3A4 and P-gp (an intestinal efflux transporter). Antibiotics Clarithromycin 500 mg Clarithromycin Cmax ↔ Whilst the changes in BID Clarithromycin AUC ↑ 19% clarithromycin parameters are not Clarithromycin Cmin ↑ 68% considered clinically relevant, the reduction in the 14-OH 14-OH-clarithromycin Cmax ↓ metabolite AUC should be 97% considered for the treatment of 14-OH-clarithromycin AUC ↓ infections caused by 97% Haemophilus influenzae in which 14-OH-clarithromycin Cmin ↓ the 14-OH metabolite is most 95% active. The increase of tipranavir Cmin may be clinically relevant. Tipranavir Cmax ↑ 40% Patients using clarithromycin at Tipranavir AUC ↑ 66% doses higher than 500 mg twice Tipranavir Cmin ↑ 100% daily should be carefully monitored for signs of toxicity of CYP 3A4 inhibition by clarithromycin and tipranavir. For tipranavir/r and P-gp (an patients with renal impairment intestinal efflux transporter) dose reduction of clarithromycin inhibition by clarithromycin. should be considered (see clarithromycin and ritonavir product information). Rifabutin 150 mg QD Rifabutin Cmax ↑ 70% Dosage reductions of rifabutin by Rifabutin AUC ↑ 190% at least 75% of the usual Rifabutin Cmin ↑ 114% 300 mg/day are recommended (ie 150 mg on alternate days, or 25-O-desacetylrifabutin Cmax ↑ three times per week). Patients 3.2 fold receiving rifabutin with Aptivus, 25-O-desacetylrifabutin AUC ↑ co-administered with low dose 21 fold ritonavir, should be closely 25-O-desacetylrifabutin Cmin ↑ monitored for emergence of 7.8 fold adverse events associated with rifabutin therapy. Further dosage Inhibition of CYP 3A4 by reduction may be necessary. tipranavir/r

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): Haemophilus influenzae (HOS-114823) rifabutin (HOS-086262) clarithromycin (HOS-084517) colchicine (HOS-086147) ritonavir (HOS-084521)

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 14

HOS-114824 · Präparat HOS-094169

No clinically significant change is observed in tipranavir PK parameters. Rifampicin Co-administration of protease Concomitant use of Aptivus, co- inhibitors with rifampicin administered with low dose substantially decreases protease ritonavir, and rifampicin is inhibitor concentrations. In the contraindicated (see section 4.3). case of tipranavir co- Alternate antimycobacterial administered with low dose agents such as rifabutin should be ritonavir, concomitant use with considered. rifampicin is expected to result in sub-optimal levels of tipranavir which may lead to loss of virologic response and possible resistance to tipranavir.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) rifabutin (HOS-086262) lead (HOS-085592) ritonavir (HOS-084521)

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 14–15

HOS-114825 · Präparat HOS-094169

14 Antimalarial Halofantrine Based on theoretical Due to their metabolic profile and Lumefantrine considerations, tipranavir, co- inherent risk of inducing torsades No interaction study administered with low dose de pointes, administration of performed ritonavir, is expected to increase halofantrine and lumefantrine halofantrine and lumefantrine with Aptivus, co-administered concentrations. with low dose ritonavir, is not recommended (see section 4.4). Inhibition of CYP 3A4 by tipranavir/r Anticonvulsants Carbamazepine 200 mg Carbamazepine total* Cmax ↑ 13% Carbamazepine should be used BID Carbamazepine total* AUC ↑ with caution in combination with 16% Aptivus, co-administered with Carbamazepine total* Cmin ↑ 23% low dose ritonavir. Higher doses of carbamazepine (> 200 mg) *Carbamazepine total = total of may result in even larger carbamazepine and epoxy- decreases in tipranavir plasma carbamazepine (both are concentrations (see section 4.4). pharmacologically active moieties).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumefantrine (HOS-114826) carbamazepine (HOS-085618) halofantrine (HOS-085606) ritonavir (HOS-084521)

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 15

HOS-114827 · Präparat HOS-094169

The increase in carbamazepine total PK parameters is not expected to have clinical consequences.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618)

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 15

HOS-114828 · Präparat HOS-094169

Tipranavir Cmin ↓ 61% (compared to historical data)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 15

HOS-114829 · Präparat HOS-094169

The decrease in tipranavir concentrations may result in decreased effectiveness.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 15

HOS-114830 · Präparat HOS-094169

Carbamazepine induces CYP3A4. Phenobarbital Phenobarbital and phenytoin Phenobarbital and phenytoin Phenytoin induce CYP3A4. should be used with caution in No interaction study combination with Aptivus, co- performed administered with low dose ritonavir (see section 4.4). Antispasmodic Tolterodine Based on theoretical Co-administration is not No interaction study considerations, tipranavir, co- recommended. performed administered with low dose ritonavir, is expected to increase tolterodine concentrations.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tolterodine (HOS-087792) phenobarbital (HOS-085617) carbamazepine (HOS-085618) ritonavir (HOS-084521) phenytoin (HOS-084531)

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 15

HOS-114831 · Präparat HOS-094169

Inhibition of CYP 3A4 and CYP 2D6 by tipranavir/r Endothelin receptor antagonists Bosentan Based on theoretical Co-administration of bosentan considerations, bosentan and Aptivus with low dose concentrations may increase upon ritonavir is not recommended co-administration with tipranavir (see section 4.4). and low dose ritonavir.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521) bosentan (HOS-086291)

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 15–16

HOS-114832 · Präparat HOS-094169

15  Inhibition of CYP 3A4 by tipranavir/r HMG CoA reductase inhibitors Atorvastatin 10 mg QD Atorvastatin Cmax ↑ 8.6 fold Co-administration of atorvastatin Atorvastatin AUC ↑ 9.4 fold and Aptivus, co-administered Atorvastatin Cmin ↑ 5.2 fold with low dose ritonavir, is not recommended. Other HMG-CoA Tipranavir ↔ reductase inhibitors should be considered such as pravastatin, Inhibition of CYP 3A4 by fluvastatin or rosuvastatin (See tipranavir/r also section 4.4 and rosuvastatin and pravastatin recommendations). In cases where co-administration is necessary, the dose of 10 mg atorvastatin daily should not be exceeded. It is recommended to start with the lowest dose and careful clinical monitoring is necessary (see section 4.4). Rosuvastatin 10 mg QD Rosuvastatin Cmax ↑ 123% Co-administration of Aptivus, co- Rosuvastatin AUC ↑ 37% administered with low dose Rosuvastatin Cmin ↑ 6% ritonavir, and rosuvastatin should be initiated with the lowest dose Tipranavir ↔ (5 mg/day) of rosuvastatin, titrated to treatment response, and Mechanism unknown. accompanied with careful clinical monitoring for rosuvastatin associated symptoms as described in the label of rosuvastatin. Pravastatin Based on similarities in the Co-administration of Aptivus, co- No interaction study elimination between pravastatin administered with low dose performed and rosuvastatin, TPV/r could ritonavir, and pravastatin should increase the plasma levels of be initiated with the lowest dose pravastatin. (10 mg/day) of pravastatin, titrated to treatment response, and Mechanism unknown. accompanied with careful clinical monitoring for pravastatin associated symptoms as described in the label of pravastatin.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) ritonavir (HOS-084521) pravastatin (HOS-086306)

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 16

HOS-114833 · Präparat HOS-094169

Simvastatin The HMG-CoA reductase The concomitant use of Aptivus, Lovastatin inhibitors simvastatin and co-administered with low dose No interaction study lovastatin are highly dependent ritonavir, with simvastatin or performed on CYP3A for metabolism. lovastatin are contra-indicated due to an increased risk of myopathy, including rhabdomyolysis (see section 4.3). HERBAL PRODUCTS St. John’s wort Plasma concentrations of Herbal preparations containing (Hypericum perforatum) tipranavir can be reduced by St. John’s wort must not be No interaction study concomitant use of the herbal combined with Aptivus, co- performed preparation St John’s wort administered with low dose (Hypericum perforatum). This is ritonavir. Co-administration of due to induction of drug Aptivus with ritonavir, with St.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) simvastatin (HOS-086158) ritonavir (HOS-084521)

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 16–17

HOS-114834 · Präparat HOS-094169

16  metabolising enzymes by St John’s wort is expected to John’s wort. substantially decrease tipranavir and ritonavir concentrations and may result in sub-optimal levels of tipranavir and lead to loss of virologic response and possible resistance to tipranavir. Inhaled beta agonists Salmeterol The concurrent administration of Concurrent administration of tipranavir and low dose ritonavir Aptivus, co-administered with may result in increased risk of low dose ritonavir, is not cardiovascular adverse events recommended. associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): salmeterol (HOS-086285) lead (HOS-085592) ritonavir (HOS-084521)